Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pioglitazone + ezetimibe
- Development stage
- Preclinical
- Lead developer
- Mankind Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pioglitazone + ezetimibe is a small molecule combination therapy being developed by Mankind Specialties for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD). The combination leverages the repurposed mechanisms of two established drugs: pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist that improves insulin sensitivity and reduces hepatic fat, and ezetimibe, a sterol absorption inhibitor that targets the Niemann-Pick C1-like 1 (NPC1L1) protein to reduce cholesterol uptake. By targeting both metabolic dysfunction and lipid accumulation, the combination aims to provide a synergistic effect in reducing liver inflammation and fibrosis. It is currently in the preclinical stage of development.
- Other names
- PioglitazoneEzetimibe
02
Targets
PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)NPC1L1 (Niemann-pick C1-Like 1 transporter)
Beyond the preview
Go deeper on pioglitazone + ezetimibe.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pioglitazone + ezetimibe.